🇺🇸 FDA

Company profile · Sponsor

Lxo

Lxo Ireland Designated Activity Company

DSGN · NYSE pharma CARLSBAD, CA, IE
Pipeline
24
Drugs
1
Patents
8

Quick answer

Lxo (DSGN) is a pharma company. headquartered in CARLSBAD, CA, IE. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker DSGN
Exchange NYSE
Company type pharma
Headquarters CARLSBAD, CA, IE
SEC CIK 0001807120

Pipeline (24)

Search pipeline →

  1. Abiraterone - Usual

    Lxo

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  2. Alectinib - Usual

    Lxo

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. Amchafibrin

    Lxo

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  4. Cloxacilin

    Lxo

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  5. Conventional medical treatment

    Lxo

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  6. Discontinuation antipsychotic treatment

    Lxo

    Psychosis Nos/Other

    phase 3 small molecule active

    1 trial

  7. ETOPOSIDE - Usual

    Lxo

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  9. Influenza vaccine

    Lxo

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  10. LV305

    Lxo

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  11. Levodopa

    Lxo

    Ischaemic Stroke

    phase 3 small molecule completed

    1 trial

  12. Paclitaxel-releasing PTA balloon catheter

    Lxo

    Arteriovenous Fistula Renal Dialysis Devices Obstruction

    phase 3 other completed

    1 trial

  13. Platelet rich plasma

    Lxo

    Coxarthrosis

    phase 3 small molecule completed

    1 trial

  14. REX-001

    Lxo

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  15. Raloxifene - Usual

    Lxo

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Rituximab

    Lxo

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  17. Topotecan - usual

    Lxo

    SCLC

    phase 3 small molecule active

    1 trial

  18. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  19. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  20. Anterior lamellar nanostructured artificial human cornea.

    Lxo

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  21. Autologous Bone Marrow Mononuclear Cells

    Lxo

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  22. Autologous adipose derived mesenchymal stem cells

    Lxo

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  23. Autologous mesenchymal stem cells from adipose tissue.

    Lxo

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  24. Bioengineered Artificial Mesenchimal Sheet (BAMS)

    Lxo

    Venous Ulcer

    phase 2 mab active

    1 trial

Drugs (1)

Search drugs →

  1. aliskiren

    RASILEZ

    C09XA02

Patents (8)

Search patents →

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12005194

    Configurable oxygen concentrator and related method

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Lxo?

Lxo (DSGN) is a pharma company. headquartered in CARLSBAD, CA, IE. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Lxo sponsor?

We track 24 ClinicalTrials.gov-linked programs for Lxo, including Abiraterone - Usual and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Lxo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.